Ex vivo stimulation of immune response against cancer with a new antigen
November 2017
Copenhagen University Hospital, Herlev, Denmark
The PD-1/PD-L1 pathway in cancer has been extensively studied whereas PD-L2 has received less attention. In the present study, the researchers used ex vivo methods to study spontaneous specific T-cell reactivity against two epitopes of PD-L2 from samples of cancer patients and healthy donors. An immune response to PD-L2 was observed, which interestingly did not cross-react with PD-L1 response. These results suggest that activating PD-L2 specific T cells might be an attractive strategy for anti-cancer immunotherapy.
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy
Mads Hald Andersen
Added on: 07-29-2021
[1] https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1390641[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
